Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Gilead Data Suggest Role For ACC Inhibition In NASH

Executive Summary

With Phase II data showing its ACC inhibitor GS-0976 can significantly reduce hepatic steatosis, Gilead moves a step closer to goal of developing a proprietary combo therapy for NASH.

You may also be interested in...



Intercept's OCA Data Bolster NASH Efficacy, But Pruritus Worries Worsen

Analysts call Intercept sell-off overblown in wake of EASL presentation of fuller Phase III data for OCA in NASH. But while depth is added to efficacy argument, pruritus concerns possibly worsen.

Pfizer Working To Catch Up In NASH With Fat-Reducing Compounds

Just moving into Phase II with a pair of candidates, Pfizer trails smaller rivals in the NASH race, but the deep-pocked firm may have the assets to develop its own proprietary combination therapy for the large-scale unmet medical need.

New Data Cast Doubt On Gilead's Phase III NASH Candidate Selonsertib

Gilead presented early data for combinations of its three mechanisms in NASH, but analysts noted the findings may undercut its lead candidate selonsertib. Plus EASL takeaways for Genfit, NGM and Madrigal.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

ID052006

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel